Two new studies from the largest single-center cohort of Susac syndrome patients reveal that small-vessel infarcts on MRI predict vision loss from retinal artery occlusions, and the complete disease triad may affect up to 70% of patients. The findings were presented at the International Stroke Conference 2026.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.
ARVO named Sangeetha Kandoi and Ellen Konadu Antwi-Adjei as the 2026 recipients of its annual Advocacy Awards. The honors recognize advocacy in eye and vision research and efforts to expand equitable access to care.
Ocular Therapeutix's experimental drug Axpaxli showed superior vision maintenance compared to Regeneron's Eylea in a late-stage wet AMD trial. Meanwhile, Ocugen reported 12-month data showing its gene therapy OCU410 reduced geographic atrophy lesions by 31%, though less than earlier interim results. Both companies are advancing toward regulatory submissions and further clinical development.
Researchers at Duke University discovered that specialized immune cells called resident macrophages maintain the eye's drainage system and regulate pressure, potentially providing a new therapeutic target for glaucoma treatment beyond current symptom management approaches.
New research links GLP-1 drugs like Ozempic to increased scurvy risk through appetite suppression and poor nutrition. University of Florida researchers are testing a GLP-1 implant for obese cats as feline obesity affects nearly 60% of US cats.
Ocular Therapeutix's Axpaxli outperformed low-dose Eylea in a Phase 3 trial for wet AMD, while Oculis Holding reported narrowed Q4 losses and expects Phase 3 trial readouts for OCS-01 in Q2 2026.
Ocugen has completed enrollment of 140 patients in its Phase 3 liMeliGhT trial for OCU400, a gene therapy for retinitis pigmentosa. Topline data expected in Q1 2027 could support potential approval later that year.
The FDA cleared NexEos Bio's IND application to proceed with a Phase II/III trial of NTX-1024 ophthalmic solution for vernal keratoconjunctivitis, following positive results from a 15-patient study in Mexico.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07246915 |
Long-term Safety & Performance of REVISYON SDS100 in Mild to Moderate Cataract: Extension Study (EB-CE-02) |
ENROLLING_BY_INVITATION | |
| NCT07073521 |
Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss |
RECRUITING | NA |
| NCT02862405 |
Perception of Objects and Natural Scenes in People With Vision Loss (ACTIVIS) |
COMPLETED | |
| NCT01838655 |
Nitisinone for Type 1B Oculocutaneous Albinism |
COMPLETED | PHASE1/PHASE2 |
| NCT01598818 |
First-Sight Refractive Error Correction in the Developing World |
COMPLETED |
